Drug & intervention

cabergoline

RxCUI 47579

Clinical trials8
Recruiting0
Related conditions18
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Cabergoline

Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth. Cabergoline is an ergot derivative and a potent dopamine D2 receptor agonist. Cabergoline was patented in 1980 and approved for medical use in 1993. It is on the World Health Organization's List of Essential Medicines.

Read on Wikipedia ↗ Wikidata Q423308 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

8 shown
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM PatientsNCT03313661 · 2017-10-14
UNKNOWN
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesNCT01794793 · 2013-06-10
COMPLETED
Cabergoline in Metastatic Breast CancerNCT01730729 · 2013-02-11
COMPLETED
Cabergoline Effect on Blood Sugar in Type 2 DiabeticsNCT01459601 · 2012-01-01
UNKNOWN
Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's DiseaseNCT00153972 · 2005-02-01
COMPLETED
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's DiseaseNCT00129181 · 2005-01-01
COMPLETED
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.NCT00174239 · 2004-07-01
TERMINATED
Effect of Cabergoline on Weight and Glucose ToleranceNCT01395602 · 2002-04-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.